SRC and cancer: Interestingly, compared to FAT1 wild‐type cancer cells, the loss of FAT1 dramatically enhances the drug sensitivity of cancer cells to dasatinib, saracatinib (SRC inhibitors), and KN93 (CAMK2 inhibitor).114